Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.70 |
| ▸ | PIK3CA | P42336 | 18/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.59 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.59 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.59 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.59 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.59 |
| ▸ | ATR | Q13535 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359067 | 0.93 | MTOR (0.80) | MTORPIK3CAPIK3CGRICTORRPTOR | |
| SCHEMBL12185941 | 0.90 | MTOR (0.87) | MTORPIK3CAPIK3CGATR | |
| SCHEMBL16684433 | 0.86 | MTOR (0.65) | MTORPIK3CAPIK3CGRICTORRPTOR | |
| SCHEMBL7920905 | 0.86 | MTOR (0.64) | MTORPIK3CAPIK3CGRICTORRPTOR | |
| SCHEMBL3145907 | 0.86 | MTOR (0.64) | MTORPIK3CAPIK3CGRICTORRPTOR | |
| SCHEMBL12138971 | 0.86 | MTOR (0.64) | MTORPIK3CAPIK3CGRICTORRPTOR | |
| Hydrochloric Acid SCHEMBL1359560 | 0.85 | MTOR (0.64) | MTORPIK3CAPIK3CGRICTORRPTOR | |
| SCHEMBL15374743 | 0.85 | MTOR (0.81) | MTORPIK3CAPIK3CGRICTORRPTOR | |
| SCHEMBL7920904 | 0.83 | MTOR (0.59) | MTORPIK3CAPIK3CGRICTORRPTOR | |
| SCHEMBL15393723 | 0.83 | MTOR (0.59) | MTORPIK3CAPIK3CGRICTORRPTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382207-B1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING CO LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| WO-2010056320-A2 | PI3K/MTOR KINASE INHIBITORS | TYROGENEX, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | MTOR 1/4885PIK3CA 2/4885PIK3CG 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.